Skip to content
DataLookout
Menu

NCT05891158

A Study About Fazirsiran in People With and Without Liver Problems

StatusCompleted
PhasePhase 1
SponsorTakeda
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 12 versions: 12 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Results posted: Nov 16, 2026
  2. Notable Results first posted: Nov 16, 2026 Show 4 more changesShow less
    • Eligibility criteria shortened, about 9 words
    • Primary endpoints revised (3)
    • Study sites: 4 to 3
    • Secondary endpoints revised (15)
  3. Minor Start date: Oct 6, 2023 to Oct 5, 2023v11
  4. Minor Start date: Oct 5, 2023 to Oct 6, 2023v10
  5. Minor Trial status: Active, Not Recruiting to Completed
    • Primary and study completion dates changed from estimate of Sep 15, 2025 to Sep 3, 2025
    v9
Show 7 earlier versionsHide 7 earlier versions
  1. Minor Primary and study completion dates: Apr 15, 2025 to Sep 15, 2025v8
  2. Minor Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 41 to confirmed 34
    • Site details revised at 4 of 4 sites
    v7
  3. Notable Eligibility criteria expanded, about 105 wordsv6
  4. Minor Primary and study completion dates: Feb 15, 2025 to Apr 15, 2025v5
  5. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Sep 25, 2023 to Oct 5, 2023
    • Site details revised at 4 of 4 sites
    v4
  6. Notable Start date: Jul 24, 2023 to Sep 25, 2023
    • Primary and study completion dates: Dec 15, 2024 to Feb 15, 2025
    v3
  7. Minor Study sites: 2 to 4v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of Fazirsiran
Timeframe: Pre-dose, 0.25, 0.5, 1, 2, 3, 4, 5, 6, 9, 24, 48, 360, 1368, 2160 and 4320 hours post-dose
Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC0-inf) of Fazirsiran
Timeframe: Pre-dose, 0.25, 0.5, 1, 2, 3, 4, 5, 6, 9, 24, 48, 360, 1368, 2160 and 4320 hours post-dose
Maximum Observed Plasma Concentration (Cmax) of Fazirsiran
Timeframe: Pre-dose, 0.25, 0.5, 1, 2, 3, 4, 5, 6, 9, 24, 48, 360, 1368, 2160 and 4320 hours post-dose

Secondary (15)

Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Number of Participants With Clinically Significant Abnormal Values for Laboratory Parameters
Number of Participants With Clinically Significant Abnormal Values for Vital Signs Parameters
Number of Participants With Clinically Significant Abnormal Values for Electrocardiogram (ECG) Parameters
Number of Participants With Clinically Significant Abnormal Values for Pulmonary Function Parameters
Show 10 moreShow less
Number of Participants With Injection Site Reactions (ISRs) by Corresponding Toxicity
Amount of Drug Excreted in Urine From Time 0 to Time 24 Hours (Ae0-24hrs) for Fazirsiran
Amount of Drug Excreted in Urine From Time 0 to Time 6 Hours (Ae0-6hrs) for Fazirsiran
Amount of Drug Excreted in Urine From Time 6 to Time 24 Hours (Ae6-24h) for Fazirsiran
Percentage of Recovered Drug in Urine Compared With the Dose (%Dose)
Renal Clearance (CLr) for Fazirsiran
Absolute Change From Baseline in Serum Alpha-1 Antitrypsin (AAT) at Nadir
Percent Change From Baseline in Serum AAT at Nadir
Absolute Change From Baseline in Serum AAT
Percent Change From Baseline in Serum AAT

Arms and interventions

Arm 1, Mild HI: Fazirsiran 200 mgExperimental

Participants with mild hepatic impairment (HI) will receive fazirsiran 200 milligrams (mg) subcutaneous (SC) injection on Day 1.

Arm 2, Moderate HI: Fazirsiran 200 mgExperimental

Participants with moderate HI will receive fazirsiran 200 mg SC injection on Day 1. The dose may be modified after review of available safety and PK data by the sponsor study team in consultation with the investigator.

Arm 3, Severe HI: Fazirsiran 200 mgExperimental

Participants with severe HI will receive fazirsiran 200 mg SC injection on Day 1. The dose may be modified after review of available safety and PK data by the sponsor study team in consultation with the investigator.

Arm 4, Normal Hepatic Function: Fazirsiran 200 mgExperimental

Participants with normal hepatic function will receive fazirsiran 200 mg SC injection on Day 1. The dose may be modified after review of available safety and PK data by the sponsor study team in consultation with the investigator.

Drugs: Fazirsiran

Sites

3 sites in 2 countries

Slovakia 2, Hungary 1